<DOC>
	<DOCNO>NCT00973453</DOCNO>
	<brief_summary>The aim study establish maximum tolerate dose PURETHAL Mites achieve 90 % patient le 20 % injection give rise swell &gt; 5 cm optimal regimen reach maximum dose determine .</brief_summary>
	<brief_title>Study With High Dose PURETHAL Mites Allergic Rhinitis/Rhinoconjunctivitis Patients</brief_title>
	<detailed_description>The tolerability safety three different initial treatment regimen PURETHAL mites patient allergic rhinitis / rhinoconjunctivitis induce house dust mite evaluate optimal regimen reach maximum tolerated dose determine . The maximum intend dose 4-fold dosage compare currently use maintenance dose PURETHAL Mites . The tolerability safety injection examine mean determine early late local systemic reaction . In addition , short-term efficacy high dose PURETHAL mites determine mean Clinical index score ( CIS ) two surrogate efficacy marker ; conjunctival provocation test ( CPT ) serum level allergen specific immunoglobulin ( IgG IgE ) . These efficacy parameter purely indicative decisive clinical development PURETHAL Mites .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>1 . Patients perennial rhinitis rhinoconjunctivitis , without mild asthma ( FEV1 &gt; 70 % ) least 2 year . allergic symptom relate HDM 2 . Positive CPT test HDM Der p , dose ≤10,000 AUeq/ml 3 . Positive SPT HDM Der p Der f ( mean wheal diameter ≥ 3mm ) 4 . Specific serum IgEtest ( ssIgE &gt; 0.7 U/ml ) HDM 5 . Age ≥ 18 year 6 . Written informed consent give 1 . Patients concomitant sensitization i.e . positive SPT ( mean wheal diameter ≥ 3 mm ) allergens HDM include clinical symptom time inclusion , relate allergen 2 . Patients sensitized pet include live together pet clinical symptom 3 . Immunotherapy ( include sublingual ) HDM within last 5 year 4 . Immunotherapy ( include sublingual ) study period 5 . Chronic asthma emphysema , particularly FEV1 ≤ 70 % predict value use inhalation corticosteroid 6 . Serious immunopathologic disease malignancy ( include autoimmune disease , tuberculosis ) 7 . Symptomatic coronary heart disease severe ( even treatment ) arterial hypertension 8 . Diseases contraindication use adrenaline 9 . Patients use aluminium preparation , e.g . antacid 10 . Severe kidney disease 11 . Use systemic steroid 12 . Treatment systemic local Betablockers immunosuppressive drug 13 . Active infection target organ ( nose eye ) 14 . Severe atopic dermatitis case systemic immunosuppressive medication use 15 . Participation clinical study new investigational drug within last 3 month 16 . Pregnancy , lactation inadequate contraceptive measure ( adequate contraceptive measure use contraceptive device pill ) 17 . Alcohol drug abuse 18 . Lack cooperation severe psychological disorder 19 . Institutionalisation official judicial order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>non-seasonal allergy</keyword>
	<keyword>house dust mite</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>dose tolerability</keyword>
</DOC>